Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Wednesday.
Several other equities analysts also recently commented on REGN. Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 3rd. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $370.00 to $396.00 and gave the company an “equal weight” rating in a research note on Friday, July 13th. Argus upped their price objective on Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the company a “buy” rating in a research note on Monday, July 16th. Canaccord Genuity reiterated a “$367.74” rating and issued a $304.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, July 19th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $340.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, July 24th. Two investment analysts have rated the stock with a sell rating, seventeen have given a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $410.95.
Regeneron Pharmaceuticals stock opened at $355.11 on Wednesday. Regeneron Pharmaceuticals has a 12 month low of $281.89 and a 12 month high of $432.50. The company has a current ratio of 3.62, a quick ratio of 2.92 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $36.71 billion, a P/E ratio of 26.48, a PEG ratio of 1.14 and a beta of 1.12.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $5.45 EPS for the quarter, beating the consensus estimate of $4.60 by $0.85. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The business had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the business earned $4.17 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 9.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post 19.31 earnings per share for the current year.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the stock in a transaction on Wednesday, August 22nd. The stock was sold at an average price of $380.49, for a total transaction of $570,735.00. Following the sale, the director now owns 1,500 shares in the company, valued at $570,735. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Michael S. Brown sold 2,000 shares of the stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $392.26, for a total value of $784,520.00. Following the sale, the director now owns 2,000 shares in the company, valued at approximately $784,520. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 110,052 shares of company stock worth $44,651,762. Company insiders own 12.42% of the company’s stock.
Several large investors have recently bought and sold shares of REGN. Icon Wealth Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $112,000. Signaturefd LLC raised its position in shares of Regeneron Pharmaceuticals by 123.8% in the second quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 198 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $159,000. Valeo Financial Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 943.4% in the second quarter. Valeo Financial Advisors LLC now owns 553 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 500 shares in the last quarter. Finally, Ingalls & Snyder LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $204,000. Hedge funds and other institutional investors own 65.95% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.